The preclinical and clinical evaluation of VB6- 845: An immunotoxin with a de-immunized payload for the systemic treatment of solid tumors

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 349-367

  Entwistle, Joycelyn ^a   Kowalski, Mark ^a   Brown, Jennifer ^a   Cizeau, Jeannick ^a   MacDonald, Glen C ^a  

^a Viventia Biotech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84911490220     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_19     Document Type: Chapter

References (59)

1. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14(3): 154-69
2. Boyiadzis M, Foon KA (2008) Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 8(8):1151-58
3. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M (2003) Anticancer antibodies. Am J Clin Pathol 119:472-85
4. Teicher BA (2009) Antibody-drug conjugate targets. Curr Cancer Drug Targets 9:982-1004
5. Hellström I, Hellström KE, Siegall CB, Trail PA (1995) Immunoconjugates and immunotoxins for therapy of carcinomas. Adv Pharmacol 33:349-88
6. Reiter Y (2001) Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 81:93-124
7. Stirpe F, Battelli MG (2006) Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci 63:1850-66
8. Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. AAPS J 8(3):E532-51
9. Van Arnum P (2008) Antibody drug conjugates: a marriage of biologics and small molecules. Pharm Technol. http://pharmtech.findpharma.com/pharmtech/Ingredients+Insider/Antibody- Drug-Conjugates-A-Marriage-of-Biologics-a/ArticleStandard/Article/detail/522139. Accessed 5 Nov 2010
10. Turturro F (2007) Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 7(1):11-17
11. Phillips GD, Li G, Duggar DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with Trastuzumab-DM1 an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290
12. Kreitman RJ, Pastan I (2006) Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 7(10):1301-11
13. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and Phase I clinical trial. Clin Cancer Res 16(6):1894-1903
14. Frankel AE (2004) Reducing the immune response to immuntotoxin. Commentary re R. Hassan et al., Pretreatment with Rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 10:13-15
15. MacDonald GC, Glover N (2005) Effective tumor targeting: strategies for the delivery of armed antibodies. Curr Opin Drug Discov Devel 8(2):177-83
16. Niv R, Cohen CJ, Denkberg G, Segal D, Reiter Y (2001) Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins. Curr Pharm Biotechnol 2:19-46
17. Brinkmann U, Keppler-Hafkemeyer A, Hafkemeyer P (2001) Recombinant immunotoxins for cancer therapy. Expert Opin Biol Ther 1(4):693-702
18. Li Z, Yu T, Zhao P, Ma J (2005) Immunotoxins and cancer therapy. Cell Mol Immunol 2(2): 106-12
19. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007) Immunotoxin treatment of cancer. Annu Rev Med 58:221-37
20. MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N (2008) A Phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with sqamous cell carcinoma of the head and neck. Drug Des Dev Ther 2:105-14
21. MacDonald GC, Rasamoelisolo M, Entwistle J, Cuthbert W, Kowalski M, Spearman MA, Glover N (2009) A Phase I clinical study of intratumorally administered VB4-845, an antiepithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck. Med Oncol 26(3):257-64
22. Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald GC (2010) A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of non muscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Devel Ther 4:313-20
23. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97(15):8548-53
24. Onda M, Beers R, Xiang L, Nagata S, Wang Q, Pastan I (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105(32):11311-16
25. Nagata S, Pastan I (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61(11):977-85
26. De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-90
27. Stas P, Lasters I (2009) Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 12(3):169-73
28. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ (2010) Immunogenicity of protein therapeutics the key causes, consequences and challenges. Self/Nonself 1(4):314-22
29. Bolognesi A, Barbieri L, Carnicelli D, Abbondanza A, Cenini P, Falasca AI, Dinota A, Stirpe F (1989) Purification and properties of a new ribosome-inactivating protein with RNA N-glycosidase activity suitable for immunotoxin preparation from the seeds of Momordica cochinchinensis. Biochim Biophys Acta 993:287-92
30. Bolognesi A, Barbieri L, Abbondanza A, Falasca AI, Carnicelli D, Battelli MG, Stirpe F (1990) Purification and properties of new ribosome-inactivating proteins with RNA N-glycosidase activity. Biochim Biophys Acta 1087:293-302
31. Barbieri L, Battelli MG, Stirpe F (1993) Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1154:237-82
32. Bolognesi A, Polito L, Tazzari PL, Lemoli RM, Lubelli C, Fogli M, Boon L, De Boer M, Stirpe F (2000) In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol 110:351-61
33. den Hartog MT, Lubelli C, Boon L, Heerkens S (2002) Ortiz Buijsse AP, de Boer M, Stirpe F. Cloning and expression of cDNA coding for bouganin. A type-I ribosome-inactivating protein from Bougainvillea spectabilis Willd. Eur J Biochem 269:1772-79
34. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC (2009) Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 32(6):574-84
35. Willuda J, Honegger A, Waibel R, Schubiger A, Stahel R, Zangemeister-Wittke U, Pluckthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 59:5758-67
36. Litvinov SV, van Driel W, van Rhijn CM, Bakker HAM, van Krieken H, Fleuren GJ, Warnaar SO (1996) Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148(3):865-75
37. Went P, Dirnhofer S, Schöpf D, Moch H, Spizzo G (2008) Expression and prognostic significance of EpCAM. J Cancer Mol 3(6):169-74
38. Ralhan R, Cao J, Lim T, MacMillan C, Freeman JL, Walfish PG (2010) EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10:331-41
39. Momburg F, Moldenhauer G, Hämmerling GJ, Möller P (1987) Immunohistochemical study of the expression of a M 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47:2883-91
40. Ogura E, Senzaki H, Yoshizawa K, Hioki K, Tsubura A (1998) Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res 18:3669-75
41. Xie X, Wang C, Cao Y, Wang W, Zhuang R, Chen L, Dang N, Fang L, Jin B (2005) Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 11(3):344-47
42. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748-58
43. Food and Drug Administration (FDA) (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use
44. Balzar M, Winter MJ, de Boer CJ, Litvinov SV (1999) The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77:699-712
45. Winter MJ, Nagtegaal ID, Han J, van Krieken JM, Litvinov SV (2003) The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163(6):2139-48
46. Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35(1):122-28
47. Brown JG, Entwistle J, Glover N, MacDonald GC (2008) Preclinical safety evaluation of immu- notoxins. In: Cavagnaro JA (ed) Preclinical safety evaluation of biopharmaceuticals. A science- based approach to facilitating clinical trials. John Wiley & Sons, Hoboken, NJ, pp 649-68
48. Brown J, Rasamoelisolo M, Spearman M, Bosc D, Cizeau J, Entwistle J, MacDonald GC (2009) Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration. Cancer Biother Radiopharm 24(4):477-87
49. Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP (1994) Prevention of immunotoxin- mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 91(20):9514-18
50. Frankel AE, Kreitman RJ, Sausville EA (2000) Targeted toxins. Clin Cancer Res 6:326-34
51. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-96
52. McLaughlin PMJ, Kroesen B, Dokter WHA, van der Molen H, de Groot M, Brinker MGL, Kok K, Ruiters MHJ, Buys CHCM, de Leij LFMH (1999) An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy. Cancer Immunol Immunother 48:303-11
53. McLaughlin PMJ, Harmsen MC, Dokter WH, Kroesen B, van der Molen H, Brinker MGL, Hollema H, Ruiters MHJ, Buys CHCM, de Leij LFMH (2001) The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 61(10):4105-11
54. Mosolits S, Campbell F, Litvinov SV, Fagerberg J, Crowe JS, Mellstedt H, Ellis JH (2004) Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines. Int J Cancer 112:669-77
55. Food and Drug Administration (FDA) (2005) Estimating the safe starting dose in clinical trial for therapeutics in adult healthy volunteers
56. Food and Drug Administration (FDA) (2006) General guide for starting dose selection for a cytotoxic agent in cancer patients. Available from http://www.fda.gov/cder/cancer/docs/ doseflow.pdf. Accessed on 3 Nov 2010
57. Wierda D, Smith HW, Zwickl CM (2001) Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158:71-74
58. Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies. Residual immunogenicity resides in the CDR regions. mAbs 2(3):256-65
59. Cizeau J, Torres MGP, Cowling SG, Stibbard S, Premsukh A, Entwistle J, MacDonald GC (2011) Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments. J Biomol Screen 16(1):90-100